Other · developed by Immunocore
HBV HCC Module MAD is a multidose study of IMC-I109V, an agent studied in chronic hepatitis B.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05867056 | Phase 1 | Hepatitis B, Chronic | Withdrawn | IMCR |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Hepatitis B, Chronic
Updated Oct 18, 2026. Something wrong or missing? Report it on the IMCR page.
See IMCR's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
IMCR catalysts and pipeline →